Unknown

Dataset Information

0

A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.


ABSTRACT: Radiolabeled bombesin (BBN) analogs that bind to the gastrin-releasing peptide receptor (GRPR) represent a topic of active investigation for the development of molecular probes for PET or SPECT of prostate cancer (PCa). RM1 and AMBA have been identified as the 2 most promising BBN peptides for GRPR-targeted cancer imaging and therapy. In this study, to develop a clinically translatable BBN-based PET probe, we synthesized and evaluated (18)F-AlF- (aluminum-fluoride) and (64)Cu-radiolabeled RM1 and AMBA analogs for their potential application in PET imaging of PCa.1,4,7-triazacyclononane, 1-glutaric acid-4,7 acetic acid (NODAGA)-conjugated RM1 and AMBA were synthesized and tested for their GRPR-binding affinities. The NODAGA-RM1 and NODAGA-AMBA probes were further radiolabeled with (64)Cu or (18)F-AlF and then evaluated in a subcutaneous PCa xenograft model (PC3) by small-animal PET imaging and biodistribution studies.NODAGA-RM1 and NODAGA-AMBA can be successfully synthesized and radiolabeled with (64)Cu and (18)F-AlF. (64)Cu- and (18)F-AlF-labeled NODAGA-RM1 demonstrated excellent serum stability and tumor-imaging properties in the in vitro stability assays and in vivo imaging studies. (64)Cu-NODAGA-RM1 exhibited tumor uptake values of 3.3 ± 0.38, 3.0 ± 0.76, and 3.5 ± 1.0 percentage injected dose per gram of tissue (%ID/g) at 0.5, 1.5, and 4 h after injection, respectively. (18)F-AlF-NODAGA-RM1 exhibited tumor uptake values of 4.6 ± 1.5, 4.0 ± 0.87, and 3.9 ± 0.48 %ID/g at 0.5, 1, and 2 h, respectively.The high-stability, efficient tumor uptake and optimal pharmacokinetic properties highlight (18)F-AlF-NODAGA-RM1 as a probe with great potential and clinical application for the PET imaging of prostate cancer.

SUBMITTER: Liu Y 

PROVIDER: S-EPMC4215198 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

A comparative study of radiolabeled bombesin analogs for the PET imaging of prostate cancer.

Liu Yang Y   Hu Xiang X   Liu Hongguang H   Bu Lihong L   Ma Xiaowei X   Cheng Kai K   Li Jinbo J   Tian Mei M   Zhang Hong H   Cheng Zhen Z  

Journal of nuclear medicine : official publication, Society of Nuclear Medicine 20131106 12


<h4>Unlabelled</h4>Radiolabeled bombesin (BBN) analogs that bind to the gastrin-releasing peptide receptor (GRPR) represent a topic of active investigation for the development of molecular probes for PET or SPECT of prostate cancer (PCa). RM1 and AMBA have been identified as the 2 most promising BBN peptides for GRPR-targeted cancer imaging and therapy. In this study, to develop a clinically translatable BBN-based PET probe, we synthesized and evaluated (18)F-AlF- (aluminum-fluoride) and (64)Cu-  ...[more]

Similar Datasets

| S-EPMC8616220 | biostudies-literature
| S-EPMC7504749 | biostudies-literature
| S-EPMC6423188 | biostudies-literature
| S-EPMC8623702 | biostudies-literature
| S-EPMC9434807 | biostudies-literature
| S-EPMC5226408 | biostudies-literature
| S-EPMC4049340 | biostudies-literature
| S-EPMC7480883 | biostudies-literature
| S-EPMC3086613 | biostudies-literature
| S-EPMC3983358 | biostudies-literature